SUN PHARMA
SUN PHARMA's Overview
Sun Pharmaceutical Industries Ltd. is the fourth largest specialty generic pharmaceutical company in the world with global revenues exceeding US$ 5.1 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe. Our R&D efforts focus on developing generics, branded generics, specialty products, over-the-counter (OTC) products, antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. We are committed to enhancing access to affordable healthcare worldwide, driven by innovation, quality, and a patient-centric approach.
Where is SUN PHARMA's Headquarters?
HQ Function
The Mumbai headquarters serves as the nerve center for global strategy formulation, corporate management, financial operations, oversight of research and development, and key decision-making processes for all of Sun Pharma's worldwide businesses.
Notable Features:
Sun House is a modern, purpose-built corporate office designed to foster collaboration and efficiency. While not famed for specific architectural awards, it stands as a significant corporate edifice equipped with contemporary amenities to support its large workforce and global functions.
Work Culture:
The work culture at Sun Pharma's headquarters is characterized by a dynamic, performance-driven, and intellectually stimulating environment. There is a strong emphasis on innovation, ethical practices, continuous learning, and a commitment to quality and excellence in the pharmaceutical domain.
HQ Significance:
Mumbai's status as India's economic powerhouse provides Sun Pharma's headquarters with unparalleled access to a rich talent pool, financial institutions, regulatory bodies, and logistical networks crucial for its vast Indian and global operations.
Values Reflected in HQ: The headquarters' modern infrastructure, strategic location, and focus on facilitating global operations reflect Sun Pharma's core values of Quality, Reliability, Trust, Innovation, and achieving Excellence.
Location:
Sun Pharma has established a robust global presence with operations in over 100 countries and more than 40 manufacturing sites across six continents. Key functions supported globally include integrated R&D for generics and specialty products, API and formulation manufacturing, stringent quality control and assurance, global regulatory affairs, and extensive sales, marketing, and distribution networks. This widespread infrastructure enables Sun Pharma to deliver affordable and innovative medicines to patients worldwide.
Street Address:
SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (East)
City:
Mumbai
State/Province:
Maharashtra
Country:
India
SUN PHARMA's Global Presence
Cranbury, New Jersey, USA
Address: 270 Prospect Plains Rd, Cranbury, NJ 08512, USA
To effectively manage and expand Sun Pharma's substantial presence in the highly competitive North American pharmaceutical market, ensuring compliance with FDA and Health Canada regulations, and driving the growth of its diverse product portfolio in the region.
Bnei Brak, Israel
Address: 12 Aba Hilel Silver Rd, BSR Tower 4, Bnei Brak, Israel (Taro Pharmaceuticals HQ - a Sun Pharma company)
Serves as a center for R&D, manufacturing, and commercial operations for Taro, contributing significantly to Sun Pharma's global dermatology and specialty product offerings, particularly in the US, Canada, and Israeli markets.
Buying Intent Signals for SUN PHARMA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of SUN PHARMA
As of April 2025, SUN PHARMA' leadership includes:
Investors of SUN PHARMA
SUN PHARMA has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Sun Pharma maintains a stable senior leadership team. Information on all executive team hires and exits across the entire global organization is not centrally published. The focus below is on major publicly announced changes at the C-suite or Board level. Over the past 12 months, there have been no major C-suite turnovers widely reported, indicating leadership stability and strategic continuity. Routine senior management appointments and transitions occur as part of ongoing business development but are not always broadly publicized.
Technology (Tech Stack) used by SUN PHARMA
Discover the tools SUN PHARMA uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
SUN PHARMA Email Formats and Examples
Sun Pharmaceutical Industries Ltd. typically utilizes standardized corporate email formats for its employees, primarily based on combinations of employee names and the official company domain, sunpharma.com. Common patterns include the first name initial followed by the last name, or the full first name separated from the last name by a dot.
[firstinitial][lastname]@sunpharma.com or [firstname].[lastname]@sunpharma.com
Format
jdoe@sunpharma.com or jane.doe@sunpharma.com
Example
90%
Success rate
News and media
The Economic Times • May 22, 2024
Sun Pharma Q4 Results: PAT jumps 34% YoY to Rs 2,654 crore, beats estimates
Sun Pharmaceutical Industries reported a 33.77% year-on-year (YoY) rise in consolidated net profit to Rs 2,654.5 crore for the March quarter (Q4 FY24). Revenue from operations increased 9.6% YoY to Rs 11,982.9 crore, surpassing market expectations....more
Reuters • January 18, 2024
India's Sun Pharma to acquire remaining shares of Taro Pharma in $307 mln deal
Sun Pharmaceutical Industries Ltd announced a definitive agreement to acquire all outstanding ordinary shares of its subsidiary Taro Pharmaceutical Industries it does not already own for $43.00 per share in cash. The deal aims to fully integrate Taro and delist it from the NYSE....more
Business Standard • November 14, 2023
Sun Pharma gets USFDA nod for Cequa to treat dry eye disease
Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has received approval from the U.S. Food and Drug Administration (USFDA) for CEQUA (cyclosporine ophthalmic solution) 0.09% for the treatment of patients with keratoconjunctivitis sicca (dry eye disease), expanding its ophthalmic portfolio in the US....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including SUN PHARMA, are just a search away.